Perinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility

Table 1 Demographic and clinical characteristics of mothers and infants

Maternal viral load (log₁₀ copies/ml)	Non-transmitting (N = 234)^a		Total transmitting (N = 79)		Intrapartum transmitting (N = 31)		In utero transmitting (N = 20)^b		In utero-enriched transmitting (N = 48)
Maternal viral load (log₁₀ copies/ml)	N^c		N^c		N^c		N^c		N^c
Median (IQR)	218	4.08 (3.20–4.67)	71	4.77 (3.77–5.34)***	27	4.77 (3.77–5.26)**	18	4.89 (4.20–5.47)***	44	4.81 (3.78–5.44)***
Maternal CD4⁺ T cell count
Mean (std)	217	520 (275)	70	418 (222)**	27	402 (179)*	15	409 (276)	43	428 (247)*
Maternal age (years)
Mean (std)	232	26.9 (5.1)	78	27.6 (5.2)	30	26.7 (5.0)	20	27.5 (5.5)	48	28.2 (5.2)
Parity
Mean (std)	231	2.1 (1.0)	77	2.3 (1.2)	29	2.3 (1.2)	20	2.2 (1.2)	48	2.3 (1.2)
Mode of delivery [N (%)]
Caesarean section	232	17 (7.3)	77	10 (13.0)	29	2 (6.9)	20	3 (15.0)	48	8 (16.7)
Gestation [N (%)]
Preterm <37 weeks	215	27 (12.6)	70	12 (17.1)	25	7 (28.0)	19	4 (21.1)	45	5 (11.1)
Child sex [N (%)]
Male	234	101 (43.1)	79	39 (49.4)	31	18 (58.0)	20	8 (40.0)	48	21 (43.8)
Birth weight (g)
Mean (std)	231	2980 (453)	78	2889 (442)	30	2943 (400)	20	2784 (320)*	48	2856 (468)
Breast fed N (%)
>3 days	233	34 (14.6)	78	10 (12.8)	30	5 (16.7)	20	2 (10.0)	48	5 (10.4)
Antiretrovirals
Nevirapine	234	114 (48.7)	79	47 (59.5)	31	11 (35.5)	20	13 (65.0)	48	36 (75.0)**
Triple drug therapy	234	6 (2.6)	79	2 (2.5)	31	0	20	0	48	2 (4.2)
Other drugs^d	234	11 (4.7)	79	6 (7.6)	31	3 (9.7)	20	1 (5.0)	48	3 (6.3)

For comparisons with non-transmitting mothers: * P < 0.05; ** P < 0.01; *** P < 0.001
^aFive unmatched mothers
^bOne unmatched mother
^cNumber of participants for whom data were available
^dDifferent regimens of zidovudine (AZT) and lamivudine (3TC)

ISSN: 1742-4690